SCLP (SCLP) News
Follow SCLP (SCLP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Scancell Holdings plc (SCLP) Secures Up To $25M Debt To Fund iSCIB1+ Phase 3
Scancell entered a loan agreement with BlackRock-managed funds for up to $25M, with $7M to be drawn after shareholder approval. Portions up to $5M are convertible; interest is 10.50%—10.95%, with warrants issued pro rata
NEWS | Sep 24, 2026, 05:03 AM UTC
L
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc AIM:SCLP (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherap
NEWS | Sep 24, 2026, 05:02 AM UTC
L
Scancell to present at H.C. Wainwright global investment conference Sept 26
Scancell Holdings plc says it will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept 26.
EQUITY | Sep 03, 2026, 01:00 PM UTC
L
Scancell to present at H.C. Wainwright 28th Annual Global Investment Conference
Scancell Holdings plc announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 12:27 PM UTC